The Future of Transient Gene Expression Keynote at PEGS Europe 2018
Prof. Dr. F. Wurm will be the keynote speaker in the Optimizing Expression Platforms conference at PEGS Summit Europe in Lisbon, Portugal on the 14-15 November 2018. The topic is Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing and will be followed by a round-table discussion later that day. For detailed information about the conference, view the PEGS Europe page on Optimising Expression Platforms. The Cambridge Health Institute and Prof. Wurm discuss foreseeable advances in transient protein expression for the next decade.
Transient protein (gene) expression (TGE) delivers products in days. HEK-293 cell TGE helped to identify a “better than nature” thrombolytic resulting in the approval of (TNKase “Tenecteplase”). Scale-up R&D resulted in the first 100 Liter–scale production in the late 1990s. Recent progress in transient protein expression, including viral vector production, delivers grams and tens of grams of high-quality protein/virus vector for preclinical research and, for clinical use soon?
- Let’s talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade?
- What potential solutions seem promising for some challenges?
- Are there promising glimpses into using transient protein gene expression for clinical use today?
- You’ll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What’s the main theme you’d like to convey to your audience of protein engineers and researchers?
We hope you enjoyed the content. Questions, comments?
©ExcellGene S.A., Route de l’Ile-aux-Bois 1A, 1870 Monthey, Switzerland.